CD-38: ARM™ – NEXT GENERATION BISPECIFIC MOLECULES
Antibody Recruiting Molecules (ARM™) are bispecific molecules that recruit endogenous antibodies to target cancer, virally infected cells, and disease-causing microorganisms for immune-mediated clearance. Similar to biologics, ARMs directly engage the immune system to destroy disease cells by connecting target disease cells with components of the immune system. ARMs are engineered as modular components that are readily interchangeable, giving the platform tremendous flexibility for a variety of indications and therapeutic areas.
MULTIPLE MYELOMA (MM)
Antibody Recruiting Molecule BHV-1100 with Autologous Memory-like Natural Killer Cell Therapy Plus Intravenous Immunoglobulin, Followed by Low-Dose IL-2 in Multiple Myeloma Patients in the Peri-autologous Stem Cell Transplant Setting
Drug: BHV-1100 | Age: 18-75 | Phase: 1
BHV-1100 is the lead clinical asset from The Antibody Recruiting Molecule (ARM™) platform and is being evaluated in an open-label single center Phase 1a/1b study in patients with newly diagnosed multiple myeloma who have tested positive for minimal residual disease (MRD+) in first or second remission prior to autologous stem cell transplant (ASCT).
BHV-1100 Binds CD38 and Ig to Create a Targeting Therapy to Kill Multiple Myeloma Cells
BHV-1100 Enhances Recruitment of NK Cells and Increases Killing of Multiple Myeloma Cells
